Results 11 to 20 of about 187,608 (218)

CXCR3 enables recruitment and site-specific bystander activation of memory CD8+ T cells

Nature Communications, 2019
T cell bystander activation is induced by systemic inflammation. Here the authors show, using mouse model systems and correlating with human vaccination data, that localized inflammation elicits bystander activation, and that CXCR3 specifically recruits ...
Nicholas J. Maurice, M. Juliana McElrath, Erica Andersen-Nissen, Nicole Frahm, Martin Prlic   +4 more
doaj   +1 more source

Persistent serum protein signatures define an inflammatory subcategory of long COVID

Nature Communications, 2023
Long COVID or post-acute sequelae of SARS-CoV-2 (PASC) is a clinical syndrome featuring diverse symptoms that can persist for months following acute SARS-CoV-2 infection.
Aarthi Talla, Suhas V. Vasaikar, Gregory Lee Szeto, Maria P. Lemos, Julie L. Czartoski, Hugh MacMillan, Zoe Moodie, Kristen W. Cohen, Lamar B. Fleming, Zachary Thomson, Lauren Okada, Lynne A. Becker, Ernest M. Coffey, Stephen C. De Rosa, Evan W. Newell, Peter J. Skene, Xiaojun Li, Thomas F. Bumol, M. Juliana McElrath, Troy R. Torgerson   +19 more
doaj   +1 more source

Identification and Validation of Th1-Selective Epitopes Derived from Proteins Overexpressed in Breast Cancer Stem Cells

Vaccines
Background: Breast cancer stem cells (CSCs), particularly those enriched in triple-negative breast cancer (TNBC), are key contributors to tumor recurrence, metastasis, and resistance to therapy. CSCs often undergo epithelial-to-mesenchymal transformation
Denise L. Cecil, Daniel Herendeen, Meredith Slota, Megan M. O’Meara, Yushe Dang, Lauren Corulli, Mary L. Disis   +6 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope

npj Vaccines
VRC01-class antibodies are a genetically restricted class of antibodies capable of potently neutralizing diverse strains of HIV-1. Unmutated VRC01 precursors fail to recognize recombinant HIV-1 Envelope (Env) proteins, which necessitated the development ...
Andrew Wilcox-King, Yu-Hsin Wan, Samuel C. Scharffenberger, Crystal B. Chhan, Amelia R. Davis, Leah J. Homad, Emilie Seydoux, Kellie J. MacPhee, Latha Kallur Siddaramaiah, Mariane Melo, Pia Dosenovic, Darrell J. Irvine, Ollivier Hyrien, Leonidas Stamatatos, Andrew T. McGuire   +14 more
doaj   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

FEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés, Luise Franz, Christian P.R. Hackenberger   +2 more
wiley   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response

Nature Communications
Humoral immune-related adverse events, including hypogammaglobulinemia and B cell depletion, pose long-term infection risks after chimeric antigen receptor T cell therapy (CARTx) for hematologic malignancies. This prospective study evaluates the kinetics
Stosh Ozog, Elizabeth M. Krantz, Karyn Tindbaek, Julian Munoz, Winnie L. Liu, Clementine Chalal, Sara Pernikoff, Khaleel Yahya, Terry Stevens-Ayers, Sayan Dasgupta, Andrew J. Cowan, Damian J. Green, Jordan Gauthier, Brian G. Till, Rebecca A. Gardner, Mazyar Shadman, Marie Bleakley, Michael Boeckh, Jim Boonyaratanakornkit, Cameron J. Turtle, Joshua A. Hill   +20 more
doaj   +1 more source